Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Case Report

Tumor Lysis Syndrome after Propranolol Therapy in Ulcerative Infantile Hemangioma: Rare Complication or Incidental Finding?

Cavalli R.a · Buffon R.B.a · de Souza M.a · Colli A.M.b · Gelmetti C.c

Author affiliations

aU.O. Dermatologia Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico di Milano, bDivision of Pediatric Cardiology, Clinica Mangiagalli, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico di Milano, and cDivision of Anesthesiology, Intensive Care Therapy and Dermatologic Sciences, Università degli Studi di Milano, Milano, Italy

Related Articles for ""

Dermatology 2012;224:106–109

Do you have an account?

Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Case Report

Received: December 02, 2011
Accepted: February 28, 2012
Published online: April 19, 2012
Issue release date: May 2012

Number of Print Pages: 4
Number of Figures: 2
Number of Tables: 0

ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)

For additional information: https://www.karger.com/DRM

Abstract

A 33-day-old female with an ulcerated infantile hemangioma (IH) undergoing oral therapy with propranolol 2 mg/kg per day developed hyperkalemia and hyperphosphatemia 24 h after starting medication. No electrocardiographic or clinical abnormalities secondary to the electrolyte changes were noticed. A laboratory tumor lysis syndrome (TLS) was diagnosed after excluding other causes of electrolyte imbalance in the diagnostic workup. No treatment was required to reverse the TLS condition, and the propranolol therapy was continued as the electrolyte alterations were only mild. One month later, the IH was remarkably reduced in size and no longer ulcerated. Maintenance of propranolol was extended for a total of 6 months. Parallel to the gradual involution of the IH, serum potassium and phosphorus levels returned within normal levels. We suggest that TLS may be a rare complication of ulcerated IH treated with propranolol. Clinicians must be aware and order appropriate screening tests for TLS in patients at risk.

© 2012 S. Karger AG, Basel


References

  1. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo J-B, Taïeb A: Propranolol for severe hemangiomas of infancy. N Engl J Med 2008;17:2649–2651.
    External Resources
  2. Hogeling M, Adams S, Wargon O: A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics 2011;128:e259–266.
    External Resources
  3. Zimmermann AP, Wiegand S, Werner JA, Eivazi B: Propranolol therapy for infantile haemangiomas: review of the literature. Int J Pediatr Otorhinol 2010;74:338–342.
  4. Storch CH, Hoeger PH: Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol 2010;163:269–274.
  5. Coiffier B, Altman A, Pui CH, Younes A, Cairo MS: Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008;26:2767–2778.
  6. Murad MH, Coto-Yglesias F, Wang AT, et al: Clinical review: drug-induced hypoglycemia: a systematic review. J Clin Endocrinol Metab 2009;94:741–745.
  7. Holland KE, Frieden IJ, Frommelt PC, et al: Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma. Arch Dermatol 2010;146:775–778.
  8. Pavlakovic H, Kietz S, Lauerer P, Zutt M, Lakomek M: Hyperkalemia complicating propranolol treatment of an infantile hemangioma. Pediatrics 2010;126:e1589–e1593.
    External Resources
  9. Rosa RM, Silva P, Young JB, et al: Adrenergic modulation of extrarenal potassium disposal. N Engl J Med 1980;302:431–434.
  10. Brown RS: Extrarenal potassium homeostasis. Kidney Int 1986;30:116–127.
  11. Hayward LJ, Kim JS, Ming-Yang L, et al: Targeted mutation of mouse skeletal muscle sodium channel produces myotonia and potassium-sensitive weakness. J Clin Invest 2008;118:1437–1449.
  12. Tannock I: Cell kinetics and chemotherapy: a critical review. Cancer Treat Rep 1978;62:1117–1133.
  13. Jona JZ: Progressive tumor necrosis and lethal hyperkalemia in a neonate with sacrococcygeal teratoma (SCT). J Perinatol 1999;19:538–540.
  14. Chang LC, Haggstrom AN, Drolet BA, et al: Growth characteristics of infantile hemangiomas: implications for management. Pediatrics 2008;122:360–367.
    External Resources
  15. Thomas RF, Hornung RL, Manning SC, et al: Hemangiomas of infancy: treatment of ulceration in the head and neck. Arch Facial Plast Surg 2005;7:312–315.
    External Resources
  16. Saint-Jean M, Léauté-Labrèze C, Mazereeuw-Hautier J, Bodak N, Hamel-Teillac D, et al: Propranolol for treatment of ulcerated infantile hemangiomas. J Am Acad Dermatol 2011;64:827–832.
  17. Kim LHC, Hogeling M, Wargon O, Jiwane A, Adams S: Propranolol: useful therapeutic agent for the treatment of ulcerated infantile hemangiomas. J Pediatr Surg 2011;46:759–763.
    External Resources
  18. Pandey A, Gangopadhyay AN, Sharma SP, et al: Conservative management of ulcerated haemangioma – twenty years’ experience. Int Wound J 2009;6:59–62.
    External Resources
  19. Metz BJ, Rubenstein MC, Levy ML, et al: Response of ulcerated perineal hemangiomas of infancy to becaplermin gel, a recombinant human platelet-derived growth factor. Arch Dermatol 2004;140:867–870.
    External Resources
  20. Cairo MS, Bishop M: Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004;127:3–11.
  21. Davidson MB, Thakkar S, Hix JK, et al: Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med 2004;116:546–554.
  22. Bishop MR, Cairo MS, Coccia PF: Tumor lysis syndrome; in Abeloff MD (ed): Clinical Oncology, ed 3. Philadelphia, Elsevier/Churchill Livingstone, 2004, pp 987–992.
  23. Rheingold S, Lange B: Oncologic emergencies; in Pizzo PA, Poplack DG (eds): Principles and Practice of Pediatric Oncology, ed 5. Philadelphia, Lippincott Williams & Wilkins, 2006, pp 1202–1230.

Article / Publication Details

First-Page Preview
Abstract of Case Report

Received: December 02, 2011
Accepted: February 28, 2012
Published online: April 19, 2012
Issue release date: May 2012

Number of Print Pages: 4
Number of Figures: 2
Number of Tables: 0

ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)

For additional information: https://www.karger.com/DRM


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.